Pharma Leaders Fireside Chat: A View of the Innate Immune System as an ‘Off-the-Shelf’ Approach to Cell Therapy

Time: 9:45 am
day: Day Two


  • Highlighting the synergies between autologous and allogeneic cell therapies to create a common chassis for development which can ‘plug and play’ with big pharma infrastructure
  • Sharing thoughts on how the intrinsic service component in the commercialization of autologous and allogeneic therapies requires similar patient preparation, additional treatment, follow up, and specialized workforce and how these fit into the ‘big pharma’ model
  • Identifying opportunities for shared synergy across different pipelines, creating an outline to develop pipelines with a common thread across the industry to facilitate collaborations, mergers, and acquisitions